| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRGN |
| Uniprot No | P10124 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-158aa |
| 氨基酸序列 | MMQKLLKCSRLVLALALILVLESSVQGYPTRRARYQWVRCNPDSNSANCL EEKGPMFELLPGESNKIPRLRTDLFPKTRIQDLNRIFPLSEDYSGSGFGS GSGSGSGSGSGFLTEMEQDYQLVDESDAFHDNLRSLDRNLPSDSQDLGQH GLEEDFML |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SRGN(Serglycin)重组蛋白相关的参考文献示例(注：文献为假设性概括，实际引用需查询具体数据库)：
---
1. **标题**：*"Recombinant Serglycin promotes tumor cell invasion via CD44-mediated signaling in colorectal cancer"*
**作者**：Chen L, et al.
**摘要**：研究通过大肠癌细胞模型，证实重组SRGN蛋白可通过与CD44受体结合激活MAPK通路，增强肿瘤细胞侵袭能力，提示其在癌症转移中的潜在作用。
2. **标题**：*"Pro-inflammatory role of recombinant Serglycin in macrophage polarization"*
**作者**：Kim J, Park S.
**摘要**：本文利用重组SRGN蛋白处理巨噬细胞，发现其通过调控NF-κB信号通路促进M1型极化，加剧炎症反应，为SRGN在免疫调节中的机制提供证据。
3. **标题**：*"Efficient expression and purification of bioactive recombinant human Serglycin in E. coli"*
**作者**：Wang Y, et al.
**摘要**：报道了一种通过大肠杆菌表达系统高效制备具有生物活性的重组人SRGN蛋白的方法，并验证其在体外实验中对蛋白酶的保护功能。
---
**提示**：实际文献需通过PubMed、Web of Science等平台以关键词“Serglycin recombinant protein”或“SRGN expression”检索，并优先选择近五年内发表的论文以获取最新进展。
Serglycin (SRGN) is a proteoglycan predominantly found in intracellular secretory granules of hematopoietic cells, such as immune cells and platelets. It plays a critical role in storing and transporting bioactive molecules, including proteases, cytokines, and histamine, by interacting with positively charged cargo via its negatively charged glycosaminoglycan (GAG) chains. Structurally, SRGN consists of a core protein backbone modified with covalently attached GAG chains (e.g., chondroitin sulfate or heparin), which determine its functional diversity. Dysregulation of SRGN has been linked to inflammation, cancer progression, and immune disorders, making it a target for therapeutic research.
Recombinant SRGN protein is engineered using biotechnological platforms (e.g., bacterial or mammalian expression systems) to study its biochemical properties and therapeutic potential. Its production enables precise investigation of SRGN's roles in extracellular matrix remodeling, cell adhesion, and signaling pathways. Notably, SRGN overexpression in tumors correlates with enhanced metastasis and chemoresistance, possibly through interactions with CD44 or modulating autophagy. Conversely, SRGN also exhibits anti-inflammatory effects in certain contexts, highlighting its functional duality.
Researchers utilize recombinant SRGN to develop inhibitors or mimetics for cancer immunotherapy, drug delivery systems (exploiting its cargo-binding capacity), and regenerative medicine. Challenges remain in replicating its native post-translational modifications, particularly GAG chain heterogeneity, which is crucial for functionality. Ongoing studies aim to optimize recombinant SRGN for clinical applications while elucidating its context-dependent mechanisms in health and disease.
×
